loading page

Children’s Oncology Group’s 2023 Blueprint for Research: Rare Tumors
  • +6
  • Kris Ann Schultz,
  • Murali Chintagumpala,
  • Jin Piao,
  • Kenneth Chen,
  • Robyn Gartrell,
  • Emily Christison-Lagay,
  • Jesse Berry,
  • Rachana Shah,
  • Theodore Laetsch
Kris Ann Schultz
Children's Minnesota Minneapolis Specialty Center

Corresponding Author:[email protected]

Author Profile
Murali Chintagumpala
Baylor College of Medicine Department of Pediatrics
Author Profile
Jin Piao
University of Southern California Keck School of Medicine
Author Profile
Kenneth Chen
The University of Texas Southwestern Medical Center
Author Profile
Robyn Gartrell
Columbia University
Author Profile
Emily Christison-Lagay
Yale School of Medicine
Author Profile
Jesse Berry
Children's Hospital Los Angeles
Author Profile
Rachana Shah
University of Southern California Keck School of Medicine
Author Profile
Theodore Laetsch
University of Pennsylvania
Author Profile


The Children’s Oncology Group (COG) Rare Tumor committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that don’t fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.
05 Jul 2023Assigned to Editor
05 Jul 2023Submission Checks Completed
05 Jul 2023Submitted to Pediatric Blood & Cancer
05 Jul 2023Review(s) Completed, Editorial Evaluation Pending
05 Jul 2023Editorial Decision: Accept